WO2012016646A9 - Quetiapine tablets - Google Patents

Quetiapine tablets Download PDF

Info

Publication number
WO2012016646A9
WO2012016646A9 PCT/EP2011/003689 EP2011003689W WO2012016646A9 WO 2012016646 A9 WO2012016646 A9 WO 2012016646A9 EP 2011003689 W EP2011003689 W EP 2011003689W WO 2012016646 A9 WO2012016646 A9 WO 2012016646A9
Authority
WO
WIPO (PCT)
Prior art keywords
quetiapine
quetiapine tablets
tablets
matrix
tablet
Prior art date
Application number
PCT/EP2011/003689
Other languages
German (de)
French (fr)
Other versions
WO2012016646A1 (en
Inventor
Klaus Neuer
Daniel Rast
Jörg BESSER
Original Assignee
Acino Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acino Pharma Ag filed Critical Acino Pharma Ag
Publication of WO2012016646A1 publication Critical patent/WO2012016646A1/en
Publication of WO2012016646A9 publication Critical patent/WO2012016646A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

The present invention relates to a tablet with a matrix of a mixture of at least two sugar alcohols, the matrix comprising, as active substance, quetiapine or a salt thereof.
PCT/EP2011/003689 2010-08-05 2011-07-22 Quetiapine tablets WO2012016646A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010033527A DE102010033527A1 (en) 2010-08-05 2010-08-05 Quetiapine tablets
DE102010033527.4 2010-08-05

Publications (2)

Publication Number Publication Date
WO2012016646A1 WO2012016646A1 (en) 2012-02-09
WO2012016646A9 true WO2012016646A9 (en) 2012-09-07

Family

ID=44630087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/003689 WO2012016646A1 (en) 2010-08-05 2011-07-22 Quetiapine tablets

Country Status (2)

Country Link
DE (1) DE102010033527A1 (en)
WO (1) WO2012016646A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005517A (en) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Crystal forms and production methods thereof.
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
KR20220018004A (en) 2019-06-04 2022-02-14 선오비온 파마슈티컬스 인코포레이티드 Controlled release formulations and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
EP1448169A1 (en) * 2001-11-07 2004-08-25 Fujisawa Pharmaceutical Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
WO2004002445A2 (en) 2002-06-26 2004-01-08 Cadila Healthcare Limited Novel floating dosage form
US20050158383A1 (en) 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
CA2613403A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2007086079A2 (en) * 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
EP1976492B8 (en) 2006-01-27 2018-07-04 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
MX350380B (en) 2006-05-09 2017-09-05 SpecGx LLC Zero-order modified release solid dosage forms.
DE102008046650A1 (en) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapine-containing prolonged-release tablet

Also Published As

Publication number Publication date
DE102010033527A1 (en) 2012-02-09
WO2012016646A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
IL259296B (en) Sodium salt of (1r,2s,5r)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
IL258908A (en) Bismuth-thiols as antiseptics for agricultural, industrial and other uses
CL2013001586A1 (en) Rapid dispersion microgranular composition comprising at least one sugar alcohol, a saccharide, or a mixture thereof, at least one super disintegrant and at least one multifunctional additive; oral disintegration tablet comprising the microgranular composition and at least one active ingredient; and manufacturing methods.
EP2522653A4 (en) Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
WO2011012816A3 (en) Pharmaceutical formulation
ZA201007679B (en) Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup,processes for their preparation and their use as pharmaceuticals
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
WO2011144674A3 (en) PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2012106665A3 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
WO2009135593A3 (en) Solid pharmaceutical formulation with delayed release
EP2630956B8 (en) Sustained-release pellets containing tacrolimus as an active ingredient
MX344846B (en) Combination of active loaded granules with additional actives.
ZA201404035B (en) Microcapsule containing fungicidal active ingredient
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
WO2014044342A8 (en) Magnesium hydroxide carbonate as carrier material in active ingredient-containing preparations
WO2010119102A3 (en) Pharmaceutical composition containing proton pump inhibitor for treating dermatological autoimmune diseases
WO2012016646A9 (en) Quetiapine tablets
HK1152652A1 (en) Pharmaceutical solid preparation having active ingredients separated by boundary therein
WO2011097527A3 (en) Immunoprotection of therapeutic moieties using enhanced fc regions
WO2011156045A3 (en) Tablet formulation of ezatiostat
EP2864328B8 (en) Pharmaceutically active compounds
EP2476420B8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
WO2015022560A8 (en) Stable pharmaceutical composition containing bisoprolol and ramipril

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743192

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 11743192

Country of ref document: EP

Kind code of ref document: A1